NorthWest Biotherapeutics Inc (NWBO)

[hankmanhub]

In short, the WHO re-classifications do not make a lot of difference in the case of our trial. L remains the best treatment prospect for the 95% wild-type, precisely because it is fully personalised, and it will probably be best for the 5% mutated IDH as well.
And there is no reason why regulators shouldn't see it this way.

THIS WAS EXACTLY THE POINT I WAS TRYING TO MAKE IN MY PREVIOUS POSTS.